Myriad Genetics Scores FDA Nod for MyChoice CDx – The Only Approved HRD Test Guiding Zejula Therapy

Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.